9 December 2015 - The US Food and Drug Administration is undertaking a speedy review of Pfizer’s kinase inhibitor Xalkori for the treatment of patients with metastatic non-small cell lung cancer whose tumours are ROS1-positive.

For more details, go to: http://www.pharmatimes.com/Article/15-12-09/Pfizer_s_Xalkori_gets_speedy_review_for_ROS1_NSCLC.aspx